The PRODIGE5/ACCORD17 trial aimed to assess the efficacy and safety of the FOLFOX treatment regimen ( fluorouracil plus leucovorin and oxaliplatin ) versus fluorouracil and cisplatin as part of chemoradiotherapy in patients with localised oesophageal cancer .